← Leaderboards
Hong Wang
Baylor College Of Medicine
$22,354,650
Attributed
$25,424,995
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2005–21$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$25,424,995 · 10
By mechanism
R01$24,898,495 · 9
K02$526,500 · 1
Top collaborators
- Eric T Choi4 shared
- Xuebin Qin4 shared
- Xiao-Feng Yang4 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Michael E. Scheurer$13,029,347
- Carl E Allen$9,873,324
- Thanh Thien Hoang$50,000
Others in their field
Top investigators on “Cardiovascular Diseases”
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$145,558,149
- Judith S. Currier · University Of California Los Angeles$143,001,230
- David M Nathan · Massachusetts Institute Of Technology$141,671,512
- John M Lachin · George Washington University$139,991,329
- Judith S Hochman · New York University School Of Medicine$112,514,057
Research focus
Cardiovascular DiseasesHomocysteineBlood VesselsRisk FactorsAtherosclerosisLeadHyperhomocysteinemiaLinkMolecularApolipoprotein EReportingCellsEndothelial CellsMediatingInsightHomocystineGenesMonocyteInflammatoryDna MethylationVascular DiseasesBiochemicalPreventIn Vivo
Grant awards (60)
CD40 monocyte in chronic kidney disease$634,794
R01 · FY2021 · DK · contact PI
CD40 monocyte in chronic kidney disease$714,044
R01 · FY2020 · DK · contact PI
Caspase-1 activation mediates chronic kidney disease-accelerated atherosclerosis$703,248
R01 · FY2019 · HL · contact PI
CD40 monocyte in chronic kidney disease$634,794
R01 · FY2019 · DK · contact PI
Atherogenic roles of complement system$596,598
R01 · FY2019 · HL · contact PI
HHcy-induced Inflammatory Monocyte and Macrophage Differentiation in Diabetes$443,251
R01 · FY2019 · DK · contact PI
CD40 monocyte in chronic kidney disease$79,250
R01 · FY2019 · DK · contact PI
Caspase-1 activation mediates chronic kidney disease-accelerated atherosclerosis$703,248
R01 · FY2018 · HL · contact PI
CD40 monocyte in chronic kidney disease$634,794
R01 · FY2018 · DK · contact PI
Atherogenic roles of complement system$608,176
R01 · FY2018 · HL
HHcy-induced Inflammatory Monocyte and Macrophage Differentiation in Diabetes$443,251
R01 · FY2018 · DK · contact PI
Caspase-1 activation mediates chronic kidney disease-accelerated atherosclerosis$703,248
R01 · FY2017 · HL · contact PI
CD40 monocyte in chronic kidney disease$634,794
R01 · FY2017 · DK · contact PI
Hyperhomocysteinemia and HDL Metabolism$620,768
R01 · FY2017 · HL · contact PI
Atherogenic roles of complement system$618,906
R01 · FY2017 · HL
HHcy-induced Inflammatory Monocyte and Macrophage Differentiation in Diabetes$443,251
R01 · FY2017 · DK · contact PI
Caspase-1 activation mediates chronic kidney disease-accelerated atherosclerosis$645,335
R01 · FY2016 · HL · contact PI
Atherogenic roles of complement system$643,572
R01 · FY2016 · HL
Hyperhomocysteinemia and HDL Metabolism$620,768
R01 · FY2016 · HL · contact PI
HHcy-induced Inflammatory Monocyte and Macrophage Differentiation in Diabetes$443,251
R01 · FY2016 · DK · contact PI
Hyperhomocysteinemia and HDL Metabolism$611,456
R01 · FY2015 · HL · contact PI
NADHP Oxidase-mediated MC differentiation & Endothelial Dysfunction in HHcy$500,550
R01 · FY2015 · HL · contact PI
HHcy-induced Inflammatory Monocyte and Macrophage Differentiation in Diabetes$443,251
R01 · FY2015 · DK · contact PI
Hyperhomocysteinemia and HDL Metabolism$522,739
R01 · FY2014 · HL · contact PI
NADHP Oxidase-mediated MC differentiation & Endothelial Dysfunction in HHcy$498,009
R01 · FY2014 · HL · contact PI
Atherogenic Mechanisms Associated with Hyperhomocysteinemia$379,894
R01 · FY2014 · HL · contact PI
Hyperhomocysteinemia and HDL Metabolism$79,995
R01 · FY2014 · HL · contact PI
Hyperhomocysteinemia and HDL Metabolism$546,657
R01 · FY2013 · HL · contact PI
NADHP Oxidase-mediated MC differentiation & Endothelial Dysfunction in HHcy$483,780
R01 · FY2013 · HL · contact PI
Atherogenic Mechanisms Associated with Hyperhomocysteinemia$369,042
R01 · FY2013 · HL · contact PI
NADHP Oxidase-mediated MC differentiation & Endothelial Dysfunction in HHcy$508,173
R01 · FY2012 · HL · contact PI
Atherogenic Mechanisms Associated with Hyperhomocysteinemia$387,648
R01 · FY2012 · HL · contact PI
NADHP Oxidase-mediated MC differentiation & Endothelial Dysfunction in HHcy$508,173
R01 · FY2011 · HL · contact PI
Atherogenic Mechanisms Associated with Hyperhomocysteinemia$390,035
R01 · FY2011 · HL · contact PI
Homocysteine and Endothelial Cell Growth Inhibition$375,000
R01 · FY2011 · HL · contact PI
Atherogenic Mechanisms Associated with Hyperhomocysteinemia$391,400
R01 · FY2010 · HL · contact PI
Homocysteine and Endothelial Cell Growth Inhibition$375,000
R01 · FY2010 · HL · contact PI
Role of HHcy in diabetic vascular disease$364,125
R01 · FY2010 · HL · contact PI
Homocysteine and Endothelial Cell Growth Inhibition$375,000
R01 · FY2009 · HL · contact PI
Role of HHcy in diabetic vascular disease$364,125
R01 · FY2009 · HL · contact PI
Homocysteine and Endothelial Cell Growth Inhibition$21,177
R01 · FY2009 · HL · contact PI
Homocysteine and Endothelial Cell Growth Inhibition$375,000
R01 · FY2008 · HL · contact PI
Role of HHcy in diabetic vascular disease$364,125
R01 · FY2008 · HL · contact PI
Atherogenic mechanisms with homocysteine$361,697
R01 · FY2008 · HL · contact PI
Homocysteine-induced Endothelial Cell Growth Inhibition$105,300
K02 · FY2008 · HL · contact PI
Role of HHcy in diabetic vascular disease$364,125
R01 · FY2007 · HL · contact PI
Atherogenic mechanisms with homocysteine$351,159
R01 · FY2007 · HL · contact PI
Homocysteine-induced Endothelial Cell Growth Inhibition$105,300
K02 · FY2007 · HL · contact PI
Role of HHcy in diabetic vascular disease$375,000
R01 · FY2006 · HL · contact PI
Atherogenic mechanisms with homocysteine$351,114
R01 · FY2006 · HL · contact PI
Homocysteine-induced Endothelial Cell Growth Inhibition$105,300
K02 · FY2006 · HL · contact PI
Atherogenic mechanisms with homocysteine$388,092
R01 · FY2005 · HL
Inhibition of Endothelial Growth by Homocysteine$337,500
R01 · FY2005 · HL
Homocysteine-induced Endothelial Cell Growth Inhibition$105,300
K02 · FY2005 · HL
Inhibition of Endothelial Growth by Homocysteine$413,875
R01 · FY2004 · HL
Atherogenic mechanisms with homocysteine$386,100
R01 · FY2004 · HL
Homocysteine-induced Endothelial Cell Growth Inhibition$105,300
K02 · FY2004 · HL
Inhibition of Endothelial Growth by Homocysteine$338,625
R01 · FY2003 · HL
Homocysteine and Embryonic Stem Cell Derived Endoth$66,918
R01 · FY2003 · HL
Inhibition of Endothelial Growth by Homocysteine$360,595
R01 · FY2002 · HL